Stocktoria
BeyondSpring Inc. BYSI
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2017-03-09
Chart by TradingView
1/9
Piotroski F — financial health
-52.32
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $0 | $0 | $0 | $1.4M | $1.4M |
| Operating income | -$8.9M | -$8.8M | -$15.1M | -$37.2M | -$66.2M |
| Net income | -$1.0M | -$11.1M | -$21.0M | -$33.3M | -$64.2M |
| Operating cash flow | -$19.8M | -$16.4M | -$16.5M | -$27.5M | -$47.2M |
| Free cash flow | -$19.8M | -$16.7M | -$16.6M | -$27.5M | -$50.1M |
| Total assets | $25.9M | $34.3M | $24.8M | $46.2M | $81.6M |
| Total liabilities | $49.9M | $48.6M | $48.3M | $49.2M | $55.3M |
| Shareholders' equity | -$24.0M | -$14.3M | -$35.3M | -$14.1M | $26.7M |
| Ratios | |||||
| Operating margin | — | — | — | -2756.4% | -4903.0% |
| Net margin | — | — | — | -2463.3% | -4750.5% |
| FCF margin | — | — | — | -2035.4% | -3707.3% |
| Return on assets | -3.9% | -32.4% | -84.8% | -72.0% | -78.6% |
| Return on equity | 4.2% | 77.9% | 59.5% | 236.3% | -240.5% |
| Debt / equity | — | — | — | — | 0.00× |
| Current ratio | 1.54 | 2.60 | 2.31 | 5.24 | 4.96 |
| Revenue growth | — | — | -100.0% | 0.0% | 650.6% |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -52.32 (distress)
- Working capital / assets 0.282
- Retained earnings / assets -15.749
- EBIT / assets -0.345
- Equity / liabilities -0.481
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001677940 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.